Research ArticleClinical Investigation
Impact of 18F-FET PET/MRI on Clinical Management of Brain Tumor Patients
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann and Christian la Fougère
Journal of Nuclear Medicine April 2022, 63 (4) 522-527; DOI: https://doi.org/10.2967/jnumed.121.262051
Cornelia Brendle
1Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany;
Caroline Maier
2Diagnostic and Interventional Radiology, Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany;
3Department of Radiology, Cantonal Hospital Muensterlingen, Muensterlingen, Switzerland;
Benjamin Bender
1Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany;
Jens Schittenhelm
4Department of Neuropathology, University Hospital Tübingen, Tuebingen, Germany;
Frank Paulsen
5Department of Radiation Oncology, University Hospital Tuebingen, Tuebingen, Germany;
Mirjam Renovanz
6Department of Neurology and Neurooncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Tübingen, Germany;
Constantin Roder
7Department of Neurosurgery, University Hospital Tübingen, Tuebingen, Germany;
Salvador Castaneda-Vega
8Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany;
9Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, and University Medical Center, Tuebingen, Germany;
Ghazaleh Tabatabai
6Department of Neurology and Neurooncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Tübingen, Germany;
Ulrike Ernemann
1Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany;
Christian la Fougère
8Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany;
10Cluster of Excellence iFIT (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies,” University of Tuebingen, Tuebingen, Germany; and
11German Cancer Consortium, Partner Site Tuebingen, Tuebingen, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 4
April 1, 2022
Impact of 18F-FET PET/MRI on Clinical Management of Brain Tumor Patients
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann, Christian la Fougère
Journal of Nuclear Medicine Apr 2022, 63 (4) 522-527; DOI: 10.2967/jnumed.121.262051
Impact of 18F-FET PET/MRI on Clinical Management of Brain Tumor Patients
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann, Christian la Fougère
Journal of Nuclear Medicine Apr 2022, 63 (4) 522-527; DOI: 10.2967/jnumed.121.262051
Jump to section
Related Articles
Cited By...
- An External, Independent Validation of an O-(2-[18F]Fluoroethyl)-L-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma
- Amino Acid PET in Neurooncology
- Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
- Amino Acid PET in Neurooncology
- Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know